Abstract
Large inter-individual variability in immunological cell composition and function determines immune responses in general and susceptibility of immune-mediated diseases in particular. While much has been learned about the genetic variants relevant for type 1 diabetes, the pathophysiological mechanisms through which these variations exert their effects are unknown. In this study, we characterize the genetic and non-genetic factors influencing immune responses in patients with type 1 diabetes. We show that age and season affect both immune cell traits and cytokine production upon stimulation. Genetic variants that determine susceptibility to T1D significantly affect T cell composition. Specifically, the CCR5+ regulatory T cells associate with T1D through the CCR region, suggesting a shared genetic regulation. Genome-wide quantitative trait loci (QTL) mapping analysis of immune traits revealed 15 genetic loci that influence immune responses in T1D. Among them, 12 have never been reported in healthy population studies, implying a disease-specific genetic regulation.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
No clinical trial included in this study.
Funding Statement
This work was supported by an ERC starting Grant (no. 948207) and a Radboud University Medical Centre Hypatia Grant (2018) to Y.L. and an ERC advanced grant (no. 833247) and a Spinoza grant of the Netherlands Association for Scientific Research to M.G.N. C.T received funding from the Perspectief Biomarker Development Center Research Programme, which is (partly) financed by the Netherlands Organisation for Scientific Research (NWO). AJ was funded by a grant from the European Foundation for the Study of Diabetes (EFSD/AZ Macrovascular Programme 2015). X.C was supported by China Scholarship Council.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The 500FG-DM study was approved by the ethical committee of Radboud University Nijmegen (NL-number: 54214.091.15). Experiments were conducted according to the principles expressed in the Declaration of Helsinki. Written informed consent was obtained from all participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵+ Shared first authors
Data Availability
Results reported in the manuscript has been summarised in supplementary tables. Codes for generating all results could be found at github (https://github.com/Chuxj/Gf_of_ip_in_T1D). Raw immune phenotype data (cell proportion and cytokine production in 300DM) and summary statistics could be found at Dryad (https://doi.org/10.5061/dryad.4f4qrfjd0). Genetics and donor information that could compromise research participant privacy are only vailable upon request to the corresponding authors (http://hfgp.bbmri.nl).
